Burg Simpson Files Product Liability Case Against DePuy Orthopaedics For Failure of Gentamicin Bone Cement
As originally reported on April 25, 2013 (DePuy’s Knee Implants Failing), patients receiving DePuy’s antibiotic-containing bone cement may be at risk of failure and loosening of their knee implants. Burg Simpson has filed a complaint in the Southern District of Ohio against DePuy Orthpaedics, Inc., and Johnson & Johnson, the parent of DePuy, on behalf of a patient who required a premature revision of her knee implant after the DePuy Gentamicin containing bone cement in her original device failed to adequately adhere to the device and bone. FDA adverse event reports indicate that the failure of DePuy’s Gentamicin (antibiotic) bone cement has resulted in loosening of joint replacement devices. Failure of the bone cement and resulting revision surgery may lead to damage to the bone and surrounding tissue.
